Surrozen (NASDAQ:SRZN – Get Free Report) and Cabaletta Bio (NASDAQ:CABA – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.
Profitability
This table compares Surrozen and Cabaletta Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Surrozen | N/A | -120.51% | -54.68% |
| Cabaletta Bio | N/A | -50.10% | -45.49% |
Analyst Recommendations
This is a breakdown of current recommendations for Surrozen and Cabaletta Bio, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Surrozen | 0 | 0 | 2 | 0 | 3.00 |
| Cabaletta Bio | 0 | 1 | 8 | 1 | 3.00 |
Valuation & Earnings
This table compares Surrozen and Cabaletta Bio”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Surrozen | $10.00 million | 3.61 | -$43.04 million | N/A | N/A |
| Cabaletta Bio | N/A | N/A | -$67.68 million | ($2.15) | -0.54 |
Surrozen has higher revenue and earnings than Cabaletta Bio.
Risk & Volatility
Surrozen has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 2.58, meaning that its share price is 158% more volatile than the S&P 500.
Insider and Institutional Ownership
66.6% of Surrozen shares are owned by institutional investors. 43.5% of Surrozen shares are owned by insiders. Comparatively, 9.9% of Cabaletta Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Cabaletta Bio beats Surrozen on 6 of the 10 factors compared between the two stocks.
About Surrozen
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
About Cabaletta Bio
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.
